CD36 and metabolic dysfunction-associated steatotic liver disease: Unveiling the molecular mechanisms underlying the HIF2α‐dependent CD36 upregulation in human hepatocytes may have notable implications for the development of new pharmacological therapies inhibiting the HIF2α/CD36 pathway trying to attenuate the excessive fat accumulation within the liver and its detrimental effects on the outcome of NAFLD.